SCHEMBL868792

SCHEMBL868792

O=S1(=O)C=CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1149072 0.81
SCHEMBL1149082 0.79
SCHEMBL10948770 0.70
SCHEMBL11478475 0.69
SCHEMBL30466385 0.69
SCHEMBL11136711 0.62
SCHEMBL449201 0.60
SCHEMBL6416766 0.60
SCHEMBL25124445 0.58
SCHEMBL1998298 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 916 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025133395-A1 BICYCLIC (HETERO)ARYLENE WRN INHIBITORY COMPOUNDS FORX THERAPEUTICS AG (CH) 2025-06-26 WO claimed
EP-4551555-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS Vividion Therapeutics, Inc. (US) 2025-05-14 EP claimed
CN-119677716-A Pharmaceutical compositions comprising WRN helicase inhibitors 维维迪恩医疗公司 2025-03-21 CN claimed
US-20240262834-A1 SYNTHESIS OF BTK INHIBITOR AND INTERMEDIATES THEREOF MERCK SHARP & DOHME LLC (US) 2024-08-08 US claimed
US-20240140915-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. 2024-05-02 US claimed
EP-4347599-A1 SYNTHESIS OF BTK INHIBITOR AND INTERMEDIATES THEREOF Merck Sharp & Dohme LLC (US) 2024-04-10 EP claimed
US-20240067612-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. 2024-02-29 US claimed
CN-117500806-A Synthesis of BTK inhibitors and intermediates thereof 默沙东有限责任公司 2024-02-02 CN claimed
WO-2024010782-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. (US) 2024-01-11 WO claimed
WO-2022251404-A1 SYNTHESIS OF BTK INHIBITOR AND INTERMEDIATES THEREOF MERCK SHARP & DOHME LLC (US) 2022-12-01 WO claimed
CN-102458581-A N- (hetero) aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo [2,3-d ] pyrimidines and pyrrol-3-yl-pyrrolo [2,3-d ] pyrimidines as JANUS kinase inhibitors INCYTE CORP 2012-05-16 CN claimed
US-20100300939-A1 Process for Removing a Contaminant from an Aromatic Selective Solvent UOP LLC (US) 2010-12-02 US claimed
US-20100270213-A1 EXTRACTIVE DISTILLATION PROCESS AND SYSTEM UOP LLC 2010-10-28 US claimed
EP-1009738-B1 SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LTD (GB) 2004-05-19 EP claimed
EP-0530537-B1 Condensed pyrimidine derivatives, their production and use as antitumor agents TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-01-08 EP claimed
EP-0530537-A1 Condensed pyrimidine derivatives, their production and use as antitumor agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-03-10 EP claimed
EP-0492316-A1 Condensed heterocyclic oligoglutamate derivatives, their production and pharmaceutical compositions containing them Takeda Chemical Industries, Ltd. (JP) 1992-07-01 EP claimed
EP-0438261-A2 Condensed heterocyclic glutamic acid derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1991-07-24 EP claimed
US-4187231-A Cyanide-catalyzed isomerization and deuterium exchange with alpha- and beta-sulfolenes PHILLIPS PETROLEUM COMPANY (US) 1980-02-05 US claimed
US-4053369-A EXTRACTIVE DISTILLATION PHILLIPS PETROLEUM COMPANY (US) 1977-10-11 US claimed